?>
Contact us
Follow Us
About Us
Members
Executive Director
Why Biosimilars
The Issue
Our Solutions
Biosimilars 101
Foundations
Core Principles
FDA Regulatory Tenets
Biosimilars FAQs
Future Evolution of Biosimilar Development
Approved Biosimilars
Advocacy
Our Action
Tools
News
Resources
Get Involved
Partners
News
Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
News
August 30, 2023
signalgroup
Biosimilars Forum Statement on CMS Announcement of Drug Negotiation List
News
August 7, 2023
signalgroup
Biosimilars Forum Scientific Publication Identifies Pathway to Streamlined Development for Biosimilars
News
July 25, 2023
signalgroup
Biosimilars Forum Applauds Boehringer Ingelheim for Launch of Cyltezo®
News
July 10, 2023
signalgroup
Biosimilars Forum Congratulates Fresenius Kabi for Launch of IDACIO®
News
July 6, 2023
signalgroup
Biosimilars Forum Applauds Sandoz for Launch of Hyrimoz®
News
July 6, 2023
signalgroup
Biosimilars Forum Applauds Organon and Samsung Bioepis for Launch of HADLIMA™
News
July 5, 2023
signalgroup
Biosimilars Forum Applauds Coherus for Launch of YUSIMRY™
News
June 30, 2023
signalgroup
Delivering on a Watershed Moment for Biosimilars and Patients
News
April 10, 2023
signalgroup
Biosimilars Key to Lowering Healthcare and Prescription Drug Costs, According to Employers
News
March 30, 2023
signalgroup
Biosimilars Forum Applauds the U.S. Senate Finance Committee for Holding PBMs Accountable for Prioritizing Profits over Patients
Prev page
01
02
03
04
05
Next page